Arcus Biosciences
RCUS
RCUS
181 hedge funds and large institutions have $1.11B invested in Arcus Biosciences in 2023 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 59 increasing their positions, 65 reducing their positions, and 23 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
9% less repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 65
1.11% less ownership
Funds ownership: 75.93% → 74.82% (-1.1%)
Holders
181
Holding in Top 10
3
Calls
$26.7M
Puts
$23.2M
Top Buyers
| 1 | +$37.9M | |
| 2 | +$26.1M | |
| 3 | +$25.3M | |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$15.2M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$14.4M |
Top Sellers
| 1 | -$23.4M | |
| 2 | -$20.9M | |
| 3 | -$19.5M | |
| 4 |
BlackRock
New York
|
-$13.5M |
| 5 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$13.2M |